from reportlab.lib.pagesizes import A4
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.lib.units import cm
from reportlab.lib import colors
from reportlab.platypus import (
    SimpleDocTemplate, Paragraph, Spacer, HRFlowable, Table, TableStyle, PageBreak
)
from reportlab.lib.enums import TA_LEFT, TA_CENTER, TA_JUSTIFY
from reportlab.platypus import KeepTogether

OUTPUT_PATH = "/home/daytona/workspace/mpharm-interview/MPharm_Interview_Answers_LungCancer.pdf"

doc = SimpleDocTemplate(
    OUTPUT_PATH,
    pagesize=A4,
    leftMargin=2.5*cm,
    rightMargin=2.5*cm,
    topMargin=2.5*cm,
    bottomMargin=2.5*cm,
    title="MPharm Interview Preparation – Lung Cancer Research",
    author="MPharm Candidate, Pharmacology Department"
)

styles = getSampleStyleSheet()

# ─── Custom Styles ─────────────────────────────────────────────────────────────
BRAND_BLUE  = colors.HexColor("#1A3C6B")
BRAND_TEAL  = colors.HexColor("#0D7377")
BRAND_LIGHT = colors.HexColor("#EAF2FB")
BRAND_GOLD  = colors.HexColor("#C9A84C")
TEXT_DARK   = colors.HexColor("#1C1C1C")

title_style = ParagraphStyle(
    "CoverTitle",
    parent=styles["Title"],
    fontSize=22,
    textColor=BRAND_BLUE,
    spaceAfter=6,
    leading=28,
    alignment=TA_CENTER,
    fontName="Helvetica-Bold"
)

subtitle_style = ParagraphStyle(
    "CoverSubtitle",
    parent=styles["Normal"],
    fontSize=12,
    textColor=BRAND_TEAL,
    spaceAfter=4,
    alignment=TA_CENTER,
    fontName="Helvetica"
)

section_heading_style = ParagraphStyle(
    "SectionHeading",
    parent=styles["Heading1"],
    fontSize=14,
    textColor=colors.white,
    backColor=BRAND_BLUE,
    spaceBefore=14,
    spaceAfter=8,
    leading=20,
    leftIndent=-0.3*cm,
    rightIndent=-0.3*cm,
    borderPad=6,
    fontName="Helvetica-Bold"
)

sub_heading_style = ParagraphStyle(
    "SubHeading",
    parent=styles["Heading2"],
    fontSize=11,
    textColor=BRAND_TEAL,
    spaceBefore=10,
    spaceAfter=4,
    fontName="Helvetica-Bold"
)

body_style = ParagraphStyle(
    "Body",
    parent=styles["Normal"],
    fontSize=10,
    textColor=TEXT_DARK,
    leading=15,
    spaceAfter=6,
    alignment=TA_JUSTIFY,
    fontName="Helvetica"
)

bullet_style = ParagraphStyle(
    "Bullet",
    parent=body_style,
    leftIndent=18,
    bulletIndent=6,
    spaceBefore=2,
    spaceAfter=3,
)

ref_style = ParagraphStyle(
    "Reference",
    parent=styles["Normal"],
    fontSize=8.5,
    textColor=colors.HexColor("#444444"),
    leading=13,
    spaceAfter=3,
    fontName="Helvetica-Oblique"
)

note_style = ParagraphStyle(
    "Note",
    parent=body_style,
    backColor=BRAND_LIGHT,
    borderPad=6,
    fontSize=9.5,
    textColor=BRAND_BLUE,
    leading=14,
    fontName="Helvetica"
)

def section_box(q_number, q_text):
    return [
        Spacer(1, 0.3*cm),
        Paragraph(f"  Q{q_number}.  {q_text}", section_heading_style),
        Spacer(1, 0.15*cm),
    ]

def sub(text):
    return Paragraph(text, sub_heading_style)

def body(text):
    return Paragraph(text, body_style)

def bullet(text):
    return Paragraph(f"•   {text}", bullet_style)

def ref(text):
    return Paragraph(text, ref_style)

def note(text):
    return Paragraph(text, note_style)

def hr():
    return HRFlowable(width="100%", thickness=0.5, color=BRAND_TEAL, spaceAfter=4)

# ─── Build Story ───────────────────────────────────────────────────────────────
story = []

# ── Cover Block ──
story.append(Spacer(1, 1.2*cm))
story.append(Paragraph("MPharm Interview Preparation", title_style))
story.append(Paragraph("Lung Cancer Research Project", subtitle_style))
story.append(Paragraph("Tata Memorial Centre, Mumbai", subtitle_style))
story.append(Spacer(1, 0.2*cm))
story.append(HRFlowable(width="60%", thickness=2, color=BRAND_GOLD, hAlign="CENTER"))
story.append(Spacer(1, 0.2*cm))
story.append(Paragraph("Pharmacology Department | M.Pharm. Research Project Application", subtitle_style))
story.append(Paragraph("Date: June 2026", subtitle_style))
story.append(Spacer(1, 1.0*cm))
story.append(note(
    "<b>Purpose of this document:</b>  This document contains professionally prepared answers to the "
    "four key interview questions expected during the MPharm research project selection process for "
    "Tata Memorial Centre, Mumbai. Each answer is backed by peer-reviewed literature and authoritative "
    "medical textbook references."
))
story.append(Spacer(1, 0.4*cm))
story.append(PageBreak())

# ══════════════════════════════════════════════════════════════════════════════
# QUESTION 1 – What is Lung Cancer?
# ══════════════════════════════════════════════════════════════════════════════
for el in section_box(1, "What is Lung Cancer?"):
    story.append(el)

story.append(sub("Definition"))
story.append(body(
    "Lung cancer, also known as bronchogenic carcinoma, is a proliferative malignant neoplasm "
    "arising from the primary respiratory epithelium of the lungs. It is broadly classified into "
    "two major histologic groups: <b>Non-Small Cell Lung Cancer (NSCLC)</b>, which accounts for "
    "approximately <b>85%</b> of all lung cancers, and <b>Small Cell Lung Cancer (SCLC)</b>, "
    "which accounts for the remaining 15%."
))
story.append(ref(
    "[1] Goldman-Cecil Medicine, International Edition, 2-Volume Set. Elsevier, 2022. "
    "Chapter: Bronchogenic Lung Cancer – Definition, p. 2024."
))
story.append(Spacer(1, 0.2*cm))

story.append(sub("Epidemiology"))
story.append(body(
    "Lung cancer is by far the <b>leading cause of cancer-related mortality globally</b>. "
    "An estimated <b>2.2 million new cases</b> are diagnosed worldwide each year, accounting for "
    "nearly 11% of all cancers and causing an estimated <b>1.8 million annual deaths</b>. "
    "Among men, lung cancer is the most common malignant neoplasm, with a worldwide incidence rate "
    "of 31.5 per 100,000. In women, the incidence (14.6 per 100,000) trails breast, cervical, and "
    "colorectal cancers but is rising. China has experienced over a <b>4.5-fold increase</b> in "
    "lung cancer-related deaths over the last 3–4 decades. In India, lung cancer kills more individuals "
    "than any other cancer type (Dr. C.S. Pramesh, Director, Tata Memorial Hospital, 2020)."
))
story.append(ref(
    "[1] Goldman-Cecil Medicine. Elsevier, 2022. Chapter: Bronchogenic Lung Cancer – Epidemiology."
))
story.append(ref(
    "[2] Smolarz B, Łukasiewicz H, Samulak D, et al. Lung Cancer–Epidemiology, Pathogenesis, "
    "Treatment and Molecular Aspect (Review of Literature). Int J Mol Sci. 2025;26(5):2049. "
    "doi: 10.3390/ijms26052049. PMID: 40076671."
))
story.append(Spacer(1, 0.2*cm))

story.append(sub("Classification (Histologic Types)"))
story.append(body("<b>A. Non-Small Cell Lung Cancer (NSCLC) – ~85% of all lung cancers</b>"))
story.append(bullet("<b>Adenocarcinoma</b> – Most common NSCLC subtype in non-smokers and women; arises peripherally; "
                    "associated with EGFR, KRAS, ALK, ROS1 mutations."))
story.append(bullet("<b>Squamous Cell Carcinoma</b> – Arises centrally from bronchial epithelium; strongly associated "
                    "with tobacco smoking; associated with p53, PTEN, PIK3CA mutations."))
story.append(bullet("<b>Large Cell Carcinoma</b> – Undifferentiated carcinoma; diagnosed by exclusion of other types."))
story.append(Spacer(1, 0.15*cm))
story.append(body("<b>B. Small Cell Lung Cancer (SCLC) – ~15% of all lung cancers</b>"))
story.append(bullet("Highly aggressive; almost exclusively associated with cigarette smoking."))
story.append(bullet("Characterized by neuroendocrine features; Rb gene mutation present in ~90% of cases."))
story.append(bullet("Responds initially to chemotherapy but has a very high rate of relapse."))
story.append(ref(
    "[1] Goldman-Cecil Medicine. Elsevier, 2022. Chapter: Bronchogenic Lung Cancer – Classification."
))
story.append(Spacer(1, 0.2*cm))

story.append(sub("Risk Factors"))
story.append(body(
    "Cigarette smoking remains the dominant risk factor, responsible for approximately <b>85% of all "
    "lung cancer cases</b>. Risk correlates with pack-years of smoking (typically ≥20 pack-years confers "
    "substantially elevated risk). Additional risk factors include:"
))
story.append(bullet("Second-hand smoke exposure (contributes to ~1% of all cases)"))
story.append(bullet("Occupational asbestos exposure (4-fold increased risk)"))
story.append(bullet("Radon gas exposure (implicated in 5–8% of cases)"))
story.append(bullet("Air pollution – particularly particulate matter (PM2.5)"))
story.append(bullet("Genetic susceptibility – family history of early lung cancer (before age 60) doubles the risk"))
story.append(bullet("Ionizing radiation exposure"))
story.append(ref(
    "[1] Goldman-Cecil Medicine. Elsevier, 2022. Chapter: Risk Factors, p. 2024–2025."
))
story.append(Spacer(1, 0.2*cm))

story.append(sub("Molecular Pathogenesis"))
story.append(body(
    "In lung adenocarcinoma, <b>nearly two-thirds of patients harbor an oncogenic mutation</b> that can "
    "potentially be targeted with specific agents. Key oncogenic drivers include:"
))
data = [
    ["Gene / Target", "Frequency", "Clinical Significance"],
    ["KRAS mutation", "~25% of adenocarcinomas", "Associated with smoking; KRAS G12C inhibitors (sotorasib, adagrasib) approved"],
    ["EGFR mutation", "~15% (White), ~40% (Asian)", "TKI therapy (gefitinib, erlotinib, osimertinib) – first-line standard of care"],
    ["ALK rearrangement", "~5% of adenocarcinomas", "Crizotinib, alectinib, brigatinib, lorlatinib approved"],
    ["ROS1 fusion", "~1–2%", "Crizotinib, entrectinib, taletrectinib approved"],
    ["RET fusion", "~1–2%", "Selpercatinib, pralsetinib approved"],
    ["MET exon 14 skip", "~3–4%", "Capmatinib, tepotinib approved"],
    ["BRAF V600E", "~2–3%", "Dabrafenib + trametinib approved"],
    ["HER2 mutation", "~2–4%", "Trastuzumab deruxtecan, sevabertinib (2025 approval)"],
    ["PD-L1 expression (≥50%)", "~30% of NSCLC", "First-line pembrolizumab monotherapy"],
]
table_style = TableStyle([
    ("BACKGROUND",    (0, 0), (-1, 0),  BRAND_BLUE),
    ("TEXTCOLOR",     (0, 0), (-1, 0),  colors.white),
    ("FONTNAME",      (0, 0), (-1, 0),  "Helvetica-Bold"),
    ("FONTSIZE",      (0, 0), (-1, -1), 8.5),
    ("BACKGROUND",    (0, 1), (-1, -1), colors.HexColor("#F5F8FD")),
    ("ROWBACKGROUNDS",(0, 1), (-1, -1), [colors.HexColor("#EAF2FB"), colors.white]),
    ("GRID",          (0, 0), (-1, -1), 0.4, colors.HexColor("#BFC9D0")),
    ("VALIGN",        (0, 0), (-1, -1), "MIDDLE"),
    ("LEFTPADDING",   (0, 0), (-1, -1), 6),
    ("RIGHTPADDING",  (0, 0), (-1, -1), 6),
    ("TOPPADDING",    (0, 0), (-1, -1), 4),
    ("BOTTOMPADDING", (0, 0), (-1, -1), 4),
])
col_widths = [3.5*cm, 3.5*cm, 9.5*cm]
t = Table(data, colWidths=col_widths, repeatRows=1)
t.setStyle(table_style)
story.append(t)
story.append(Spacer(1, 0.15*cm))
story.append(ref(
    "[1] Goldman-Cecil Medicine. Elsevier, 2022. Oncogenes – Lung Cancer section, p. 2025–2026."
))
story.append(ref(
    "[3] Meyer ML, Fitzgerald BG, Paz-Ares L, et al. New promises and challenges in the treatment of "
    "advanced non-small-cell lung cancer. Lancet. 2024 Aug 24. doi: 10.1016/S0140-6736(24)01029-8. "
    "PMID: 39121882."
))
story.append(Spacer(1, 0.2*cm))

story.append(sub("Tumor Suppressor Gene Alterations"))
story.append(body(
    "Loss of tumor suppressor gene function is a hallmark of lung cancer. Mutations or loss of "
    "<b>p53</b> are detected in ~50% of NSCLC and ~80% of SCLC, correlating with cigarette smoking. "
    "Deletion of chromosome 3p occurs in ~50% of NSCLC and ~90% of SCLC. "
    "The <b>Rb gene</b> is not expressed in 90% of SCLC due to mutation or deletion."
))
story.append(ref(
    "[1] Goldman-Cecil Medicine. Elsevier, 2022. Tumor Suppressor Genes – Lung Cancer, p. 2026."
))

story.append(PageBreak())

# ══════════════════════════════════════════════════════════════════════════════
# QUESTION 2 – Purpose of Internship and Why Tata Memorial?
# ══════════════════════════════════════════════════════════════════════════════
for el in section_box(2, "What is the Purpose of This Internship, and Why at Tata Memorial?"):
    story.append(el)

story.append(sub("Purpose of the MPharm Research Internship"))
story.append(body(
    "The primary purpose of this internship is to conduct focused, supervised research in the "
    "domain of <b>cancer pharmacology</b>, with a specific emphasis on <b>lung cancer therapeutics</b>. "
    "As a candidate in the MPharm Pharmacology programme, this internship provides the opportunity to:"
))
story.append(bullet(
    "<b>Translate academic pharmacological knowledge into applied research</b> – understanding how "
    "laboratory findings are developed into clinical drug candidates."
))
story.append(bullet(
    "<b>Gain exposure to cutting-edge molecular oncology</b> – including biomarker analysis, "
    "drug sensitivity assays, and molecular targeted therapy mechanisms in lung cancer."
))
story.append(bullet(
    "<b>Develop research competencies</b> – experimental design, data analysis, scientific writing, "
    "and presentation of findings in a high-throughput research environment."
))
story.append(bullet(
    "<b>Contribute to ongoing clinical/translational research</b> – by working alongside multidisciplinary "
    "oncology teams comprising oncologists, pathologists, molecular biologists, and pharmacists."
))
story.append(bullet(
    "<b>Explore pharmacological resistance mechanisms</b> – a major challenge in lung cancer treatment, "
    "particularly secondary resistance to EGFR-TKIs (e.g., T790M mutation) and immunotherapy resistance."
))
story.append(Spacer(1, 0.2*cm))

story.append(sub("Why Tata Memorial Centre, Mumbai?"))
story.append(body(
    "Tata Memorial Centre (TMC) is India's premier and oldest cancer research and treatment institution, "
    "established in 1941. It operates under the administrative control of the "
    "<b>Department of Atomic Energy, Government of India</b>, and has national and international recognition "
    "from the <b>WHO, IAEA, and UICC</b> as a leading oncology training centre. There are several compelling "
    "reasons why TMC is the ideal setting for this research project:"
))
story.append(Spacer(1, 0.1*cm))

story.append(Paragraph("1. Unmatched Clinical Volume and Research Infrastructure", sub_heading_style))
story.append(body(
    "TMC registers approximately <b>120,000 new cancer patients annually</b> across its network, making "
    "it one of the highest-volume cancer institutions in the world. This provides unparalleled access "
    "to patient data, tissue samples, and clinical outcomes for research purposes. "
    "The <b>Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)</b> at Kharghar, "
    "Navi Mumbai – a constituent of TMC – houses the <b>Integrated Cancer Genomics Laboratory</b>, "
    "Bone Marrow Transplant Unit, Proton Therapy Centre, and Clinical Research Centre, all directly "
    "relevant to lung cancer research."
))
story.append(ref(
    "[4] Tata Memorial Centre, Official Website. tmc.gov.in. Accessed June 2026."
))
story.append(ref(
    "[5] Wikipedia: Tata Memorial Centre. https://en.wikipedia.org/wiki/Tata_Memorial_Centre. Accessed June 2026."
))

story.append(Paragraph("2. National Leadership in Lung Cancer Research", sub_heading_style))
story.append(body(
    "TMC is at the forefront of lung cancer research in India. Researchers from TMC's Department of "
    "Medical Oncology and Pathology have co-authored landmark multi-centre studies including the "
    "<b>'Uniqueness of Lung Cancer in Southeast Asia'</b> (published 2024), characterizing the distinct "
    "molecular epidemiology of lung cancer in Asian populations – including higher prevalence of "
    "EGFR mutations in never-smokers and adenocarcinoma subtype dominance. This directly informs "
    "drug development and therapeutic strategy at TMC."
))
story.append(ref(
    "[6] Pramesh CS, et al. (Tata Memorial Hospital). Uniqueness of lung cancer in Southeast Asia. "
    "PMC11328770. PMID: 39157507. Published 2024."
))

story.append(Paragraph("3. Evidence-Based Medicine and Multidisciplinary Team (MDT) Approach", sub_heading_style))
story.append(body(
    "TMC has spearheaded the <b>Evidence-Based Medicine (EBM) movement</b> in oncology in India and "
    "uses a rigorous Multidisciplinary Team (MDT) model for patient management. For a pharmacology "
    "researcher, this environment offers direct interaction between clinical outcomes and pharmacological "
    "interventions – an irreplaceable learning experience."
))

story.append(Paragraph("4. Affiliation with Homi Bhabha National Institute (HBNI)", sub_heading_style))
story.append(body(
    "TMC is a post-graduate teaching centre affiliated to <b>Homi Bhabha National Institute (HBNI)</b>. "
    "This affiliation ensures that research conducted at TMC meets internationally rigorous academic "
    "standards, and findings contribute directly to peer-reviewed scientific literature. "
    "Approximately <b>80 post-graduate students</b> register at TMC annually for Master's or Doctorate "
    "programmes, reinforcing the academic research ecosystem."
))
story.append(ref(
    "[4] Tata Memorial Centre, Official Website. tmc.gov.in. Accessed June 2026."
))

story.append(Paragraph("5. Drug Discovery and Novel Therapeutics Focus", sub_heading_style))
story.append(body(
    "TMC has established a dedicated facility at Khopoli for <b>drug discovery using Indian traditional "
    "and medicinal plant knowledge</b> to develop cheaper, less toxic anti-cancer drugs. This aligns "
    "perfectly with an MPharm research focus in pharmacology – specifically identifying novel drug "
    "candidates or repurposing existing molecules against lung cancer targets."
))
story.append(ref(
    "[7] Press Information Bureau, Govt. of India. Cancer Treatment Centres Under Tata Memorial Centre "
    "and DAE. pib.gov.in. Accessed June 2026."
))

story.append(PageBreak())

# ══════════════════════════════════════════════════════════════════════════════
# QUESTION 3 – Future Goals
# ══════════════════════════════════════════════════════════════════════════════
for el in section_box(3, "What are Your Future Goals?"):
    story.append(el)

story.append(body(
    "My future goals are aligned with the global and national need for improved pharmacological "
    "interventions in lung cancer, which remains the leading cause of cancer mortality worldwide. "
    "These goals are structured across three interconnected domains:"
))
story.append(Spacer(1, 0.15*cm))

story.append(sub("1. Short-Term Goal: Completion of MPharm Research Project at Tata Memorial Centre"))
story.append(body(
    "In the immediate term, my goal is to successfully complete a focused, hypothesis-driven "
    "research project in lung cancer pharmacology at Tata Memorial Centre. This project aims to "
    "contribute original data to one or more of the following areas:"
))
story.append(bullet(
    "Investigation of <b>drug resistance mechanisms</b> in EGFR-mutant NSCLC (e.g., secondary T790M "
    "mutation, MET amplification, EMT-mediated resistance) and identification of pharmacological "
    "strategies to overcome resistance."
))
story.append(bullet(
    "Evaluation of <b>novel targeted drug candidates</b> or drug combinations against lung cancer "
    "cell lines using in vitro cytotoxicity assays, apoptosis studies, and molecular pathway analysis."
))
story.append(bullet(
    "Contribution to the <b>pharmacogenomics of lung cancer</b> in the Indian population – "
    "understanding how genetic variations influence drug response and toxicity in Asian patients, "
    "who exhibit a higher prevalence of EGFR mutations (~40%) compared to Western populations (~15%)."
))
story.append(ref(
    "[1] Goldman-Cecil Medicine. Elsevier, 2022. EGFR mutation frequencies, p. 2025–2026."
))
story.append(ref(
    "[2] Smolarz B et al. Int J Mol Sci. 2025;26(5):2049. PMID: 40076671."
))
story.append(Spacer(1, 0.2*cm))

story.append(sub("2. Medium-Term Goal: PhD and Independent Research Career"))
story.append(body(
    "Following the completion of my MPharm, I plan to pursue a <b>PhD in Cancer Pharmacology or "
    "Molecular Oncology</b> – ideally in a continuation of my MPharm research. The PhD will be "
    "directed toward:"
))
story.append(bullet(
    "Developing a <b>preclinical pipeline</b> for novel anti-lung cancer agents, bridging in vitro "
    "findings to in vivo animal models."
))
story.append(bullet(
    "Investigating <b>antibody-drug conjugates (ADCs)</b> as next-generation lung cancer therapies, "
    "given the recent clinical validation of agents like trastuzumab deruxtecan and "
    "datopotamab deruxtecan in EGFR+ NSCLC (FDA approved 2025)."
))
story.append(bullet(
    "Exploring <b>immunotherapy biomarkers</b> – particularly for Indian patients with lung cancer, "
    "where PD-L1 expression patterns and tumour mutational burden (TMB) profiles may differ from "
    "Western cohorts."
))
story.append(ref(
    "[3] Meyer ML et al. Lancet. 2024. PMID: 39121882. ADCs and bispecific antibodies in NSCLC."
))
story.append(ref(
    "[8] Lung Cancer Research Foundation. FDA Approvals in Lung Cancer Treatment. "
    "lungcancerresearchfoundation.org. Accessed June 2026."
))
story.append(Spacer(1, 0.2*cm))

story.append(sub("3. Long-Term Goal: Advancing Cancer Drug Policy and Accessibility in India"))
story.append(body(
    "Lung cancer in India presents a unique public health challenge – a significant number of "
    "patients are never-smokers with EGFR-mutant adenocarcinoma, and the cost of targeted therapies "
    "remains prohibitive for the majority of the population. My long-term vision is to:"
))
story.append(bullet(
    "Contribute to the <b>development of affordable generic or biosimilar targeted therapies</b> "
    "for lung cancer, aligned with India's national cancer control programme."
))
story.append(bullet(
    "Publish high-impact peer-reviewed research that informs <b>national treatment guidelines</b> "
    "for lung cancer pharmacotherapy in India."
))
story.append(bullet(
    "Work at the interface of pharmacology, clinical oncology, and drug policy to help close the "
    "<b>treatment access gap</b> between urban specialty centres (like TMC) and peripheral hospitals."
))
story.append(bullet(
    "Potentially contribute to <b>novel drug discovery using Indian medicinal plants</b>, as "
    "TMC's Khopoli facility has demonstrated potential for identifying cheaper, less toxic "
    "anti-cancer agents from indigenous botanical sources."
))
story.append(ref(
    "[6] Pramesh CS et al. Uniqueness of lung cancer in Southeast Asia. PMC11328770. 2024."
))
story.append(ref(
    "[7] Press Information Bureau. pib.gov.in. Accessed June 2026."
))

story.append(PageBreak())

# ══════════════════════════════════════════════════════════════════════════════
# QUESTION 4 – Marketed Drugs for Lung Cancer
# ══════════════════════════════════════════════════════════════════════════════
for el in section_box(4, "What are the Marketed Drugs Available for Lung Cancer?"):
    story.append(el)

story.append(body(
    "Lung cancer pharmacotherapy has undergone a paradigm shift over the past two decades, "
    "transitioning from non-specific cytotoxic chemotherapy to molecularly targeted, biomarker-driven "
    "treatment. Approved therapies are broadly categorised into the following classes:"
))
story.append(Spacer(1, 0.15*cm))

# Table 1: Conventional Chemotherapy
story.append(sub("A. Conventional Cytotoxic Chemotherapy"))
story.append(body(
    "Platinum-based doublet chemotherapy remains the backbone for advanced NSCLC without actionable "
    "mutations and for SCLC."
))
chemo_data = [
    ["Drug (Brand Name)", "Class", "Indication"],
    ["Cisplatin / Carboplatin", "Platinum analogue", "NSCLC + SCLC – first-line (doublet backbone)"],
    ["Paclitaxel (Taxol®)", "Taxane", "NSCLC – in combination with platinum"],
    ["Docetaxel (Taxotere®)", "Taxane", "NSCLC – second-line monotherapy"],
    ["Pemetrexed (Alimta®)", "Antifolate", "Non-squamous NSCLC – first & second line"],
    ["Etoposide (VePesid®)", "Topoisomerase II inhibitor", "SCLC – first-line + platinum"],
    ["Gemcitabine (Gemzar®)", "Antimetabolite", "NSCLC squamous – first-line + platinum"],
    ["Vinorelbine (Navelbine®)", "Vinca alkaloid", "NSCLC – single agent or combination"],
    ["Irinotecan (Camptosar®)", "Topoisomerase I inhibitor", "SCLC – alternative combination regimen"],
]
t2 = Table(chemo_data, colWidths=[4.5*cm, 4.5*cm, 7.5*cm], repeatRows=1)
t2.setStyle(table_style)
story.append(t2)
story.append(ref(
    "[1] Goldman-Cecil Medicine. Elsevier, 2022. Treatment of Lung Cancer, p. 2027–2029."
))
story.append(Spacer(1, 0.25*cm))

# Table 2: EGFR TKIs
story.append(sub("B. EGFR Tyrosine Kinase Inhibitors (TKIs)"))
story.append(body(
    "Indicated for NSCLC with activating EGFR mutations (exon 19 deletions, exon 21 L858R, exon 20 "
    "T790M). Three generations of EGFR-TKIs are available."
))
egfr_data = [
    ["Drug (Brand Name)", "Generation", "Key Indication"],
    ["Gefitinib (Iressa®)", "1st generation", "EGFR-mutant NSCLC – first-line"],
    ["Erlotinib (Tarceva®)", "1st generation", "EGFR-mutant NSCLC – first-line; also maintenance"],
    ["Afatinib (Giotrif®)", "2nd generation", "EGFR exon 19/21 mutant NSCLC – first-line"],
    ["Dacomitinib (Vizimpro®)", "2nd generation", "EGFR-mutant NSCLC – first-line"],
    ["Osimertinib (Tagrisso®)", "3rd generation", "EGFR T790M resistant NSCLC; first-line (exon 19/21)"],
    ["Sunvozertinib (Zegfrovy®)", "3rd generation", "EGFR exon 20 insertion mutations – FDA approved July 2025"],
]
t3 = Table(egfr_data, colWidths=[4.5*cm, 3.5*cm, 8.5*cm], repeatRows=1)
t3.setStyle(table_style)
story.append(t3)
story.append(ref(
    "[1] Goldman-Cecil Medicine. Elsevier, 2022. EGFR TKI therapy, p. 2025–2027."
))
story.append(ref(
    "[9] FDA. Novel Drug Approvals 2025. fda.gov. Accessed June 2026."
))
story.append(Spacer(1, 0.25*cm))

# Table 3: ALK/ROS1/RET inhibitors
story.append(sub("C. ALK / ROS1 / RET / MET / KRAS Targeted Agents"))
fusion_data = [
    ["Drug (Brand Name)", "Target", "Indication"],
    ["Crizotinib (Xalkori®)", "ALK, ROS1, MET", "ALK+ or ROS1+ NSCLC – first-line (older standard)"],
    ["Ceritinib (Zykadia®)", "ALK", "ALK+ NSCLC – post-crizotinib"],
    ["Alectinib (Alecensa®)", "ALK", "ALK+ NSCLC – preferred first-line"],
    ["Brigatinib (Alunbrig®)", "ALK", "ALK+ NSCLC – first-line"],
    ["Lorlatinib (Lorbrena®)", "ALK, ROS1", "ALK+ NSCLC – after first/second-gen TKI failure"],
    ["Ensartinib (Ensacove™)", "ALK", "ALK+ NSCLC – first-line, FDA approved Dec 2024"],
    ["Entrectinib (Rozlytrek®)", "ROS1, NTRK1-3", "ROS1+ NSCLC; NTRK fusion solid tumours"],
    ["Taletrectinib (Ibtrozi™)", "ROS1, NTRK", "ROS1+ NSCLC – FDA approved June 2025"],
    ["Selpercatinib (Retevmo®)", "RET", "RET fusion+ NSCLC"],
    ["Pralsetinib (Gavreto®)", "RET", "RET fusion+ NSCLC"],
    ["Capmatinib (Tabrecta®)", "MET", "MET exon 14 skipping NSCLC"],
    ["Tepotinib (Tepmetko®)", "MET", "MET exon 14 skipping NSCLC"],
    ["Sotorasib (Lumakras®)", "KRAS G12C", "KRAS G12C+ NSCLC – first KRAS inhibitor approved"],
    ["Adagrasib (Krazati®)", "KRAS G12C", "KRAS G12C+ NSCLC – post-platinum chemotherapy"],
    ["Dabrafenib + Trametinib", "BRAF V600E + MEK", "BRAF V600E mutant NSCLC"],
]
t4 = Table(fusion_data, colWidths=[4.5*cm, 3.5*cm, 8.5*cm], repeatRows=1)
t4.setStyle(table_style)
story.append(t4)
story.append(ref(
    "[1] Goldman-Cecil Medicine. Elsevier, 2022. Molecular targeted therapy section."
))
story.append(ref(
    "[8] Lung Cancer Research Foundation. FDA Approvals in Lung Cancer Treatment. lungcancerresearchfoundation.org."
))
story.append(Spacer(1, 0.25*cm))

story.append(PageBreak())

# Table 4: Immunotherapy
story.append(sub("D. Immune Checkpoint Inhibitors (ICIs)"))
story.append(body(
    "Checkpoint inhibitors targeting the PD-1/PD-L1 axis have transformed the treatment of NSCLC "
    "without actionable mutations, particularly in tumours with high PD-L1 expression (≥50%). "
    "They are also used in combination with chemotherapy for broader benefit."
))
immuno_data = [
    ["Drug (Brand Name)", "Target", "Key Indication"],
    ["Pembrolizumab (Keytruda®)", "PD-1", "First-line monotherapy (PD-L1 ≥50%) or + chemo"],
    ["Nivolumab (Opdivo®)", "PD-1", "Second-line NSCLC; neoadjuvant + adjuvant (FDA Oct 2024)"],
    ["Atezolizumab (Tecentriq®)", "PD-L1", "First-line NSCLC with high PD-L1; extensive SCLC"],
    ["Durvalumab (Imfinzi®)", "PD-L1", "Stage III NSCLC post-CRT; limited-stage SCLC (Dec 2024)"],
    ["Ipilimumab (Yervoy®)", "CTLA-4", "Combo with nivolumab – PD-L1+ metastatic NSCLC"],
    ["Cemiplimab (Libtayo®)", "PD-1", "First-line NSCLC PD-L1 ≥50%"],
    ["Tarlatamab (Imdelltra®)", "DLL3 x CD3 bispecific", "Extensive-stage SCLC – full FDA approval Nov 2025"],
]
t5 = Table(immuno_data, colWidths=[4.5*cm, 3.2*cm, 8.8*cm], repeatRows=1)
t5.setStyle(table_style)
story.append(t5)
story.append(ref(
    "[3] Meyer ML et al. Lancet. 2024. PMID: 39121882. Immune checkpoint inhibitors in NSCLC."
))
story.append(ref(
    "[8] Lung Cancer Research Foundation. FDA Approvals. lungcancerresearchfoundation.org. 2024–2025."
))
story.append(Spacer(1, 0.25*cm))

# Table 5: ADCs
story.append(sub("E. Antibody-Drug Conjugates (ADCs) – Emerging Class"))
story.append(body(
    "ADCs represent a major advancement in lung cancer therapy, combining the targeting specificity "
    "of monoclonal antibodies with the cytotoxic potency of chemotherapeutic payloads."
))
adc_data = [
    ["Drug (Brand Name)", "Target", "Indication & Status"],
    ["Trastuzumab deruxtecan (Enhertu®)", "HER2", "HER2-mutant/overexpressing NSCLC"],
    ["Datopotamab deruxtecan (Datroway®)", "TROP-2", "EGFR+ NSCLC post-TKI+chemo – FDA accelerated approval June 2025"],
    ["Telisotuzumab vedotin (Emrelis™)", "c-MET", "Non-squamous NSCLC with high MET – FDA approved May 2025"],
    ["Zenocutuzumab (Bizengri®)", "NRG1 fusion", "NRG1 fusion+ NSCLC – FDA accelerated approval Dec 2024"],
]
t6 = Table(adc_data, colWidths=[5.0*cm, 2.8*cm, 8.7*cm], repeatRows=1)
t6.setStyle(table_style)
story.append(t6)
story.append(ref(
    "[8] Lung Cancer Research Foundation. FDA Approvals in Lung Cancer Treatment. 2024–2025. "
    "lungcancerresearchfoundation.org. Accessed June 2026."
))
story.append(ref(
    "[9] FDA. Novel Drug Approvals 2025. fda.gov. Accessed June 2026."
))
story.append(Spacer(1, 0.25*cm))

# Table 6: Angiogenesis
story.append(sub("F. Anti-Angiogenic Agents"))
antiangio_data = [
    ["Drug (Brand Name)", "Target / Class", "Indication"],
    ["Bevacizumab (Avastin®)", "VEGF-A monoclonal antibody", "Non-squamous NSCLC – in combination with chemotherapy"],
    ["Ramucirumab (Cyramza®)", "VEGFR-2 monoclonal antibody", "NSCLC – second-line + docetaxel; also + erlotinib (EGFR mutant)"],
    ["Nintedanib (Vargatef®)", "VEGFR, PDGFR, FGFR TKI", "Adenocarcinoma NSCLC – second-line + docetaxel (EMA approved)"],
]
t7 = Table(antiangio_data, colWidths=[4.0*cm, 4.5*cm, 8.0*cm], repeatRows=1)
t7.setStyle(table_style)
story.append(t7)
story.append(ref(
    "[1] Goldman-Cecil Medicine. Elsevier, 2022. Anti-angiogenic therapy in lung cancer."
))
story.append(Spacer(1, 0.25*cm))

story.append(sub("G. Novel 2025 Approvals – Summary"))
story.append(body(
    "In 2025, seven new FDA approvals were granted for NSCLC alone, reflecting the unprecedented pace "
    "of targeted therapy development:"
))
story.append(bullet("Sunvozertinib (Zegfrovy®) – EGFR exon 20 insertion (July 2025)"))
story.append(bullet("Taletrectinib (Ibtrozi™) – ROS1+ NSCLC (June 2025)"))
story.append(bullet("Telisotuzumab vedotin (Emrelis™) – MET-overexpressing NSCLC (May 2025)"))
story.append(bullet("Datopotamab deruxtecan (Datroway®) – EGFR+ NSCLC post-TKI/chemo (June 2025)"))
story.append(bullet("Sevabertinib (Hyrnuo®) – HER2 TKD-mutant NSCLC (November 2025)"))
story.append(bullet("Tarlatamab (Imdelltra®) – Extensive-stage SCLC, full approval (November 2025)"))
story.append(bullet("Lurbinectedin + atezolizumab (Zepzelca® + Tecentriq®) – Extensive SCLC maintenance (October 2025)"))
story.append(ref(
    "[9] FDA. Novel Drug Approvals 2025. fda.gov. Accessed June 2026."
))
story.append(ref(
    "[10] ASCO Post. New FDA-Approved Oncology Drugs. December 2025. ascopost.com. Accessed June 2026."
))
story.append(ref(
    "[11] PMC. A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets. "
    "PMC12873738. Accessed June 2026."
))

story.append(PageBreak())

# ══════════════════════════════════════════════════════════════════════════════
# FULL REFERENCE LIST
# ══════════════════════════════════════════════════════════════════════════════
story.append(Paragraph("  References", section_heading_style))
story.append(Spacer(1, 0.2*cm))

references = [
    "[1] Goldman-Cecil Medicine, International Edition, 2-Volume Set. Elsevier, 2022. "
    "Chapter 177: Bronchogenic Lung Cancer (Definition, Epidemiology, Risk Factors, Molecular "
    "Pathogenesis, Oncogenes, Tumor Suppressor Genes, Staging, Treatment). Pages 2024–2031.",

    "[2] Smolarz B, Łukasiewicz H, Samulak D, Piekarska E, Kołaciński R, Romanowicz H. "
    "Lung Cancer–Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature). "
    "International Journal of Molecular Sciences. 2025;26(5):2049. "
    "doi: 10.3390/ijms26052049. PMID: 40076671.",

    "[3] Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Jänne PA, Peters S. "
    "New promises and challenges in the treatment of advanced non-small-cell lung cancer. "
    "Lancet. 2024 Aug 24. doi: 10.1016/S0140-6736(24)01029-8. PMID: 39121882.",

    "[4] Tata Memorial Centre. Official Website. Available at: https://tmc.gov.in. Accessed June 2026.",

    "[5] Wikipedia: Tata Memorial Centre. "
    "https://en.wikipedia.org/wiki/Tata_Memorial_Centre. Accessed June 2026.",

    "[6] Pramesh CS, et al. (Corresponding: Dept of Medical Oncology, Tata Memorial Hospital). "
    "Uniqueness of lung cancer in Southeast Asia. "
    "PMCID: PMC11328770. PMID: 39157507. Published 2024.",

    "[7] Press Information Bureau, Government of India. Parliament Question: Cancer Treatment Centres "
    "and Hospitals Under Tata Memorial Centre and DAE. pib.gov.in. Accessed June 2026.",

    "[8] Lung Cancer Research Foundation. FDA Approvals in Lung Cancer Treatment. "
    "https://www.lungcancerresearchfoundation.org/research/why-research/treatment-advances. "
    "Accessed June 2026.",

    "[9] U.S. Food and Drug Administration. Novel Drug Approvals for 2025. "
    "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025. Accessed June 2026.",

    "[10] ASCO Post. New FDA-Approved Oncology Drugs and Label Updates Between December 1, 2024 "
    "and November 19, 2025. ascopost.com. Accessed June 2026.",

    "[11] PMC. A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets. "
    "PMC12873738. Accessed June 2026.",

    "[12] Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume Set. Elsevier, 2022. "
    "Chapters: Treatment of Non-Small Cell Lung Cancer by Stage; Staging of Lung Cancer.",

    "[13] Bouchard N, Daaboul N. Lung Cancer: Targeted Therapy in 2025. Curr Oncol. 2025 Mar 2. "
    "PMID: 40136350.",

    "[14] Jeon H, Wang S, Song J. Update 2025: Management of Non-Small-Cell Lung Cancer. Lung. "
    "2025 Mar 25. PMID: 40133478.",
]

for r in references:
    story.append(ref(r))
    story.append(Spacer(1, 0.08*cm))

story.append(Spacer(1, 0.5*cm))
story.append(HRFlowable(width="100%", thickness=0.5, color=BRAND_GOLD))
story.append(Spacer(1, 0.2*cm))
story.append(Paragraph(
    "Document prepared for: MPharm Research Project Interview – Tata Memorial Centre, Mumbai | June 2026",
    ParagraphStyle("Footer", parent=body_style, fontSize=8, textColor=colors.grey, alignment=TA_CENTER)
))

# ── Build PDF ──
doc.build(story)
print(f"PDF successfully generated: {OUTPUT_PATH}")

<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8"/>
<style>
  @page {
    size: A4;
    margin: 2.2cm 2.5cm 2.2cm 2.5cm;
  }
  * { box-sizing: border-box; margin: 0; padding: 0; }
  body {
    font-family: Arial, Helvetica, sans-serif;
    font-size: 10.5pt;
    color: #1a1a1a;
    line-height: 1.55;
    background: white;
  }

  /* ── Cover ── */
  .cover {
    text-align: center;
    padding: 60px 20px 40px;
    border-bottom: 4px solid #1A3C6B;
    margin-bottom: 30px;
    page-break-after: always;
  }
  .cover h1 {
    font-size: 22pt;
    color: #1A3C6B;
    margin-bottom: 8px;
  }
  .cover h2 {
    font-size: 15pt;
    color: #0D7377;
    font-weight: normal;
    margin-bottom: 6px;
  }
  .cover .gold-line {
    width: 180px;
    height: 3px;
    background: #C9A84C;
    margin: 14px auto;
  }
  .cover .meta {
    font-size: 10pt;
    color: #555;
    margin-top: 8px;
  }
  .cover .note-box {
    margin: 30px auto 0;
    max-width: 500px;
    background: #EAF2FB;
    border-left: 4px solid #1A3C6B;
    padding: 14px 16px;
    font-size: 9.5pt;
    color: #1A3C6B;
    text-align: left;
    border-radius: 4px;
  }

  /* ── Section Heading (question bar) ── */
  .q-heading {
    background: #1A3C6B;
    color: white;
    font-size: 12.5pt;
    font-weight: bold;
    padding: 9px 14px;
    margin: 30px 0 12px 0;
    border-radius: 3px;
    page-break-after: avoid;
  }

  /* ── Sub headings ── */
  h3 {
    font-size: 11pt;
    color: #0D7377;
    margin: 16px 0 5px 0;
    page-break-after: avoid;
  }

  /* ── Body text ── */
  p {
    margin-bottom: 7px;
    text-align: justify;
  }

  /* ── Bullets ── */
  ul {
    margin: 4px 0 8px 22px;
  }
  ul li {
    margin-bottom: 4px;
  }

  /* ── Tables ── */
  table {
    width: 100%;
    border-collapse: collapse;
    font-size: 9pt;
    margin: 10px 0 6px 0;
    page-break-inside: auto;
  }
  thead tr {
    background: #1A3C6B;
    color: white;
  }
  thead th {
    padding: 7px 8px;
    text-align: left;
    font-weight: bold;
  }
  tbody tr:nth-child(even) { background: #EAF2FB; }
  tbody tr:nth-child(odd)  { background: #F9FBFD; }
  tbody td {
    padding: 6px 8px;
    border: 0.5px solid #C8D6E0;
    vertical-align: top;
  }

  /* ── Reference block ── */
  .ref {
    font-size: 8.5pt;
    color: #555;
    font-style: italic;
    margin: 2px 0;
    line-height: 1.4;
  }
  .ref-section {
    margin-top: 10px;
    padding-top: 6px;
    border-top: 1px solid #C8D6E0;
  }

  /* ── Note box ── */
  .note {
    background: #EAF2FB;
    border-left: 4px solid #0D7377;
    padding: 9px 12px;
    font-size: 9.5pt;
    color: #1A3C6B;
    margin: 8px 0;
    border-radius: 3px;
  }

  /* ── Page break ── */
  .page-break { page-break-before: always; }

  /* ── Footer ── */
  .footer {
    text-align: center;
    font-size: 8pt;
    color: #888;
    border-top: 1px solid #C9A84C;
    padding-top: 8px;
    margin-top: 40px;
  }

  /* ── Reference list ── */
  .ref-list ol {
    margin-left: 18px;
    font-size: 8.5pt;
    color: #444;
    font-style: italic;
    line-height: 1.6;
  }
  .ref-list ol li { margin-bottom: 5px; }
</style>
</head>
<body>

<!-- ══════════ COVER PAGE ══════════ -->
<div class="cover">
  <h1>MPharm Interview Preparation</h1>
  <h2>Lung Cancer Research Project</h2>
  <h2>Tata Memorial Centre, Mumbai</h2>
  <div class="gold-line"></div>
  <p class="meta">Pharmacology Department &nbsp;|&nbsp; M.Pharm. Research Project Application</p>
  <p class="meta">Date: June 2026</p>
  <div class="note-box">
    <strong>Purpose of this document:</strong> This document contains professionally prepared answers
    to the four key interview questions expected during the MPharm research project selection process
    for Tata Memorial Centre, Mumbai. Each answer is backed by peer-reviewed literature and
    authoritative medical textbook references.
  </div>
</div>

<!-- ══════════ Q1 ══════════ -->
<div class="q-heading">Q1. What is Lung Cancer?</div>

<h3>Definition</h3>
<p>
  Lung cancer, also termed <strong>bronchogenic carcinoma</strong>, is a proliferative malignant
  neoplasm arising from the primary respiratory epithelium of the lungs. It is broadly classified
  into two major histologic groups: <strong>Non-Small Cell Lung Cancer (NSCLC)</strong>, which
  accounts for approximately <strong>85%</strong> of all lung cancers, and
  <strong>Small Cell Lung Cancer (SCLC)</strong>, which constitutes the remaining ~15%.
</p>
<div class="ref-section">
  <p class="ref">[1] Goldman-Cecil Medicine, International Edition, 2-Volume Set. Elsevier, 2022.
  Chapter: Bronchogenic Lung Cancer – Definition, p. 2024.</p>
</div>

<h3>Epidemiology</h3>
<p>
  Lung cancer is by far the <strong>leading cause of cancer-related mortality globally</strong>.
  An estimated <strong>2.2 million new cases</strong> are diagnosed worldwide each year, accounting
  for nearly 11% of all cancers and causing an estimated <strong>1.8 million annual deaths</strong>.
  Among men, lung cancer is the most common malignant neoplasm worldwide (incidence rate: 31.5 per
  100,000). In women, the incidence (14.6 per 100,000) trails breast, cervical, and colorectal
  cancers but continues to rise. China has experienced over a <strong>4.5-fold increase</strong> in
  lung cancer-related deaths over 3–4 decades. In India, lung cancer kills more individuals than
  any other cancer type (Dr. C.S. Pramesh, Director, Tata Memorial Hospital, 2020).
</p>
<div class="ref-section">
  <p class="ref">[1] Goldman-Cecil Medicine. Elsevier, 2022. Bronchogenic Lung Cancer – Epidemiology.</p>
  <p class="ref">[2] Smolarz B, Łukasiewicz H, Samulak D, et al. Lung Cancer–Epidemiology, Pathogenesis,
  Treatment and Molecular Aspect (Review of Literature). Int J Mol Sci. 2025;26(5):2049.
  doi:10.3390/ijms26052049. PMID: 40076671.</p>
</div>

<h3>Classification (Histologic Types)</h3>
<p><strong>A. Non-Small Cell Lung Cancer (NSCLC) – ~85% of all lung cancers</strong></p>
<ul>
  <li><strong>Adenocarcinoma</strong> – Most common NSCLC subtype; occurs peripherally; common in
  non-smokers and women; associated with EGFR, KRAS, ALK, ROS1 mutations.</li>
  <li><strong>Squamous Cell Carcinoma</strong> – Arises centrally from bronchial epithelium; strongly
  linked to tobacco smoking; associated with p53, PTEN, PIK3CA mutations.</li>
  <li><strong>Large Cell Carcinoma</strong> – Undifferentiated; diagnosed by exclusion of other
  types; poor prognosis.</li>
</ul>
<p><strong>B. Small Cell Lung Cancer (SCLC) – ~15% of all lung cancers</strong></p>
<ul>
  <li>Highly aggressive; almost exclusively associated with cigarette smoking.</li>
  <li>Characterised by neuroendocrine features; Rb gene mutation present in ~90% of cases.</li>
  <li>Responds initially to chemotherapy but has a very high relapse rate.</li>
</ul>
<div class="ref-section">
  <p class="ref">[1] Goldman-Cecil Medicine. Elsevier, 2022. Chapter: Classification of Lung Cancer.</p>
</div>

<h3>Risk Factors</h3>
<p>
  Cigarette smoking is responsible for approximately <strong>85% of all lung cancer cases</strong>.
  Risk correlates with pack-years (typically ≥20 pack-years confers substantially elevated risk).
  Additional risk factors include:
</p>
<ul>
  <li>Second-hand smoke exposure (~1% of all cases)</li>
  <li>Occupational asbestos exposure (4-fold increased risk)</li>
  <li>Radon gas exposure (implicated in 5–8% of cases)</li>
  <li>Air pollution – particularly particulate matter (PM2.5)</li>
  <li>Genetic susceptibility – family history of early lung cancer (before age 60) doubles the risk</li>
  <li>Ionizing radiation exposure</li>
</ul>
<div class="ref-section">
  <p class="ref">[1] Goldman-Cecil Medicine. Elsevier, 2022. Risk Factors, p. 2024–2025.</p>
</div>

<h3>Molecular Pathogenesis and Oncogenic Drivers</h3>
<p>
  In lung adenocarcinoma, <strong>nearly two-thirds of patients harbour an oncogenic mutation</strong>
  that can potentially be targeted with specific agents. Key drivers are tabulated below:
</p>
<table>
  <thead>
    <tr><th>Gene / Target</th><th>Frequency</th><th>Clinical Significance</th></tr>
  </thead>
  <tbody>
    <tr><td>KRAS mutation</td><td>~25% of adenocarcinomas</td><td>KRAS G12C inhibitors (sotorasib, adagrasib) approved</td></tr>
    <tr><td>EGFR mutation</td><td>~15% (White); ~40% (Asian)</td><td>TKI therapy (gefitinib, erlotinib, osimertinib) – standard of care</td></tr>
    <tr><td>ALK rearrangement</td><td>~5%</td><td>Crizotinib, alectinib, brigatinib, lorlatinib approved</td></tr>
    <tr><td>ROS1 fusion</td><td>~1–2%</td><td>Crizotinib, entrectinib, taletrectinib (2025) approved</td></tr>
    <tr><td>RET fusion</td><td>~1–2%</td><td>Selpercatinib, pralsetinib approved</td></tr>
    <tr><td>MET exon 14 skipping</td><td>~3–4%</td><td>Capmatinib, tepotinib approved</td></tr>
    <tr><td>BRAF V600E</td><td>~2–3%</td><td>Dabrafenib + trametinib approved</td></tr>
    <tr><td>HER2 mutation</td><td>~2–4%</td><td>Trastuzumab deruxtecan, sevabertinib (2025)</td></tr>
    <tr><td>PD-L1 expression (≥50%)</td><td>~30% of NSCLC</td><td>First-line pembrolizumab monotherapy</td></tr>
  </tbody>
</table>
<div class="ref-section">
  <p class="ref">[1] Goldman-Cecil Medicine. Elsevier, 2022. Oncogenes – Lung Cancer, p. 2025–2026.</p>
  <p class="ref">[3] Meyer ML, Fitzgerald BG, Paz-Ares L, et al. New promises and challenges in the
  treatment of advanced NSCLC. Lancet. 2024 Aug 24. doi:10.1016/S0140-6736(24)01029-8. PMID: 39121882.</p>
</div>

<h3>Tumor Suppressor Gene Alterations</h3>
<p>
  Mutations or loss of <strong>p53</strong> are detected in ~50% of NSCLC and ~80% of SCLC,
  correlating with cigarette smoking. Deletion of chromosome 3p occurs in ~50% of NSCLC and ~90%
  of SCLC. The <strong>Rb gene</strong> is not expressed in ~90% of SCLC due to mutation or deletion.
</p>
<div class="ref-section">
  <p class="ref">[1] Goldman-Cecil Medicine. Elsevier, 2022. Tumor Suppressor Genes – Lung Cancer, p. 2026.</p>
</div>

<!-- ══════════ Q2 ══════════ -->
<div class="page-break"></div>
<div class="q-heading">Q2. What is the Purpose of This Internship, and Why at Tata Memorial?</div>

<h3>Purpose of the MPharm Research Internship</h3>
<p>
  The primary purpose of this internship is to conduct focused, supervised research in the domain
  of <strong>cancer pharmacology</strong>, with a specific emphasis on
  <strong>lung cancer therapeutics</strong>. This internship will enable me to:
</p>
<ul>
  <li><strong>Translate academic pharmacological knowledge into applied research</strong> – understanding
  how laboratory findings are developed into clinical drug candidates.</li>
  <li><strong>Gain exposure to cutting-edge molecular oncology</strong> – including biomarker analysis,
  drug sensitivity assays, and molecular targeted therapy mechanisms in lung cancer.</li>
  <li><strong>Develop core research competencies</strong> – experimental design, data analysis,
  scientific writing, and presentation of findings in a high-throughput research environment.</li>
  <li><strong>Contribute to ongoing translational research</strong> – by working alongside
  multidisciplinary oncology teams (oncologists, pathologists, molecular biologists, pharmacists).</li>
  <li><strong>Explore pharmacological resistance mechanisms</strong> – particularly secondary
  resistance to EGFR-TKIs (e.g., T790M mutation, MET amplification) and immunotherapy resistance,
  which are the foremost clinical challenges in lung cancer today.</li>
</ul>

<h3>Why Tata Memorial Centre, Mumbai?</h3>
<p>
  Tata Memorial Centre (TMC) is India's premier and oldest cancer research and treatment institution,
  established in 1941. It operates under the administrative control of the
  <strong>Department of Atomic Energy, Government of India</strong>, and is internationally
  recognized by the <strong>WHO, IAEA, and UICC</strong>. There are five compelling reasons
  to pursue this project at TMC:
</p>

<h3>1. Unmatched Clinical Volume and Research Infrastructure</h3>
<p>
  TMC registers approximately <strong>120,000 new cancer patients annually</strong> across its
  network – one of the highest volumes in the world. This provides unparalleled access to patient
  data, tissue samples, and clinical outcomes. The
  <strong>Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)</strong> at
  Kharghar, Navi Mumbai – a TMC constituent – houses the
  <strong>Integrated Cancer Genomics Laboratory</strong>, Bone Marrow Transplant Unit, Proton
  Therapy Centre, and Clinical Research Centre, all directly relevant to lung cancer research.
</p>
<div class="ref-section">
  <p class="ref">[4] Tata Memorial Centre. Official Website. tmc.gov.in. Accessed June 2026.</p>
  <p class="ref">[5] Wikipedia: Tata Memorial Centre. https://en.wikipedia.org/wiki/Tata_Memorial_Centre.
  Accessed June 2026.</p>
</div>

<h3>2. National Leadership in Lung Cancer Research</h3>
<p>
  TMC is at the forefront of lung cancer research in India. Researchers from TMC's Department of
  Medical Oncology and Pathology co-authored the landmark multicenter study
  <em>"Uniqueness of Lung Cancer in Southeast Asia"</em> (2024), characterizing the distinct
  molecular epidemiology of lung cancer in Asian populations – including higher prevalence of EGFR
  mutations in never-smokers and adenocarcinoma subtype dominance. This directly informs drug
  development strategy at TMC.
</p>
<div class="ref-section">
  <p class="ref">[6] Pramesh CS et al. (Tata Memorial Hospital). Uniqueness of lung cancer in
  Southeast Asia. PMCID: PMC11328770. PMID: 39157507. Published 2024.</p>
</div>

<h3>3. Evidence-Based Medicine and Multidisciplinary Team (MDT) Approach</h3>
<p>
  TMC has spearheaded the <strong>Evidence-Based Medicine (EBM) movement</strong> in oncology in
  India and uses a rigorous Multidisciplinary Team (MDT) model for all patient management. For a
  pharmacology researcher, this environment enables direct correlation between clinical outcomes
  and pharmacological interventions.
</p>

<h3>4. Affiliation with Homi Bhabha National Institute (HBNI)</h3>
<p>
  TMC is affiliated with <strong>Homi Bhabha National Institute (HBNI)</strong> and is a recognized
  post-graduate teaching centre. Approximately <strong>80 post-graduate students</strong> register
  annually for Master's or Doctorate programmes. Research at TMC meets internationally rigorous
  academic standards and directly contributes to peer-reviewed scientific literature.
</p>
<div class="ref-section">
  <p class="ref">[4] Tata Memorial Centre. Official Website. tmc.gov.in. Accessed June 2026.</p>
</div>

<h3>5. Drug Discovery and Novel Therapeutics Focus</h3>
<p>
  TMC has established a dedicated facility at Khopoli for <strong>drug discovery using Indian
  traditional medicinal plant knowledge</strong> to develop cheaper, less toxic anti-cancer drugs.
  This directly aligns with an MPharm research focus in pharmacology – identifying novel drug
  candidates or repurposing existing molecules against lung cancer molecular targets.
</p>
<div class="ref-section">
  <p class="ref">[7] Press Information Bureau, Govt. of India. Cancer Treatment Centres Under Tata
  Memorial Centre and DAE. pib.gov.in. Accessed June 2026.</p>
</div>

<!-- ══════════ Q3 ══════════ -->
<div class="page-break"></div>
<div class="q-heading">Q3. What are Your Future Goals?</div>

<p>
  My future goals are aligned with the global and national urgency for improved pharmacological
  interventions in lung cancer. They are structured across three interconnected domains:
</p>

<h3>1. Short-Term Goal: Completion of MPharm Research Project at TMC</h3>
<p>
  In the immediate term, my goal is to complete a focused, hypothesis-driven research project
  in lung cancer pharmacology at Tata Memorial Centre. This project aims to contribute original
  data in one or more of the following areas:
</p>
<ul>
  <li>Investigation of <strong>drug resistance mechanisms</strong> in EGFR-mutant NSCLC (e.g.,
  T790M secondary mutation, MET amplification, EMT-mediated resistance) and identification of
  pharmacological strategies to overcome resistance.</li>
  <li>Evaluation of <strong>novel targeted drug candidates or drug combinations</strong> against
  lung cancer cell lines using in vitro cytotoxicity assays, apoptosis studies, and molecular
  pathway analysis.</li>
  <li>Contribution to the <strong>pharmacogenomics of lung cancer in the Indian population</strong>
  – understanding how genetic variations influence drug response and toxicity in Asian patients,
  who show a higher prevalence of EGFR mutations (~40%) compared to Western populations (~15%).</li>
</ul>
<div class="ref-section">
  <p class="ref">[1] Goldman-Cecil Medicine. Elsevier, 2022. EGFR mutation frequency data, p. 2025–2026.</p>
  <p class="ref">[2] Smolarz B et al. Int J Mol Sci. 2025;26(5):2049. PMID: 40076671.</p>
</div>

<h3>2. Medium-Term Goal: PhD and Independent Research Career</h3>
<p>
  Following MPharm completion, I plan to pursue a <strong>PhD in Cancer Pharmacology or Molecular
  Oncology</strong> – ideally as a continuation of my MPharm research. The PhD will be directed
  toward:
</p>
<ul>
  <li>Developing a <strong>preclinical pipeline</strong> for novel anti-lung cancer agents,
  bridging in vitro findings to in vivo animal models.</li>
  <li>Investigating <strong>Antibody-Drug Conjugates (ADCs)</strong> as next-generation lung
  cancer therapies, given the recent clinical validation of agents like datopotamab deruxtecan
  in EGFR+ NSCLC (FDA approved June 2025) and telisotuzumab vedotin in MET-overexpressing
  NSCLC (FDA approved May 2025).</li>
  <li>Exploring <strong>immunotherapy biomarkers</strong> – particularly for Indian patients,
  where PD-L1 expression patterns and tumour mutational burden (TMB) profiles may differ
  from Western cohorts.</li>
</ul>
<div class="ref-section">
  <p class="ref">[3] Meyer ML et al. Lancet. 2024. PMID: 39121882. ADCs and bispecific antibodies in NSCLC.</p>
  <p class="ref">[8] Lung Cancer Research Foundation. FDA Approvals in Lung Cancer.
  lungcancerresearchfoundation.org. Accessed June 2026.</p>
</div>

<h3>3. Long-Term Goal: Advancing Cancer Drug Policy and Accessibility in India</h3>
<p>
  Lung cancer in India presents a unique public health challenge. A significant proportion of
  patients are never-smokers with EGFR-mutant adenocarcinoma, and the cost of targeted therapies
  remains prohibitive for most of the population. My long-term vision includes:
</p>
<ul>
  <li>Contributing to the <strong>development of affordable generic or biosimilar targeted
  therapies</strong> for lung cancer, aligned with India's national cancer control programme.</li>
  <li>Publishing high-impact peer-reviewed research that informs <strong>national treatment
  guidelines</strong> for lung cancer pharmacotherapy in India.</li>
  <li>Working at the interface of pharmacology, clinical oncology, and drug policy to help
  close the <strong>treatment access gap</strong> between urban specialty centres and
  peripheral hospitals.</li>
  <li>Potentially contributing to <strong>drug discovery using Indian medicinal plants</strong>,
  as TMC's Khopoli facility has demonstrated potential for identifying cheaper, less toxic
  anti-cancer agents from indigenous botanical sources.</li>
</ul>
<div class="ref-section">
  <p class="ref">[6] Pramesh CS et al. PMC11328770. 2024.</p>
  <p class="ref">[7] Press Information Bureau. pib.gov.in. Accessed June 2026.</p>
</div>

<!-- ══════════ Q4 ══════════ -->
<div class="page-break"></div>
<div class="q-heading">Q4. What are the Marketed Drugs Available for Lung Cancer?</div>

<p>
  Lung cancer pharmacotherapy has undergone a remarkable transformation over the past two decades,
  shifting from non-specific cytotoxic chemotherapy to molecularly targeted, biomarker-driven
  treatment. Approved therapies are categorised into the following major classes:
</p>

<h3>A. Conventional Cytotoxic Chemotherapy</h3>
<p>Platinum-based doublet chemotherapy remains the backbone for advanced NSCLC without actionable
mutations and for all stages of SCLC.</p>
<table>
  <thead>
    <tr><th>Drug (Brand Name)</th><th>Class</th><th>Indication</th></tr>
  </thead>
  <tbody>
    <tr><td>Cisplatin / Carboplatin</td><td>Platinum analogue</td><td>NSCLC + SCLC – first-line doublet backbone</td></tr>
    <tr><td>Paclitaxel (Taxol®)</td><td>Taxane</td><td>NSCLC – in combination with platinum</td></tr>
    <tr><td>Docetaxel (Taxotere®)</td><td>Taxane</td><td>NSCLC – second-line monotherapy</td></tr>
    <tr><td>Pemetrexed (Alimta®)</td><td>Antifolate</td><td>Non-squamous NSCLC – first and second line</td></tr>
    <tr><td>Etoposide (VePesid®)</td><td>Topoisomerase II inhibitor</td><td>SCLC – first-line with platinum</td></tr>
    <tr><td>Gemcitabine (Gemzar®)</td><td>Antimetabolite</td><td>NSCLC squamous – first-line + platinum</td></tr>
    <tr><td>Vinorelbine (Navelbine®)</td><td>Vinca alkaloid</td><td>NSCLC – single agent or combination</td></tr>
    <tr><td>Irinotecan (Camptosar®)</td><td>Topoisomerase I inhibitor</td><td>SCLC – alternative combination regimen</td></tr>
  </tbody>
</table>
<div class="ref-section">
  <p class="ref">[1] Goldman-Cecil Medicine. Elsevier, 2022. Treatment of Lung Cancer, p. 2027–2029.</p>
</div>

<h3>B. EGFR Tyrosine Kinase Inhibitors (TKIs)</h3>
<p>Indicated for NSCLC with activating EGFR mutations (exon 19 deletions, exon 21 L858R). Three
generations are available, each addressing resistance mechanisms of the prior generation.</p>
<table>
  <thead>
    <tr><th>Drug (Brand Name)</th><th>Generation</th><th>Key Indication</th></tr>
  </thead>
  <tbody>
    <tr><td>Gefitinib (Iressa®)</td><td>1st generation</td><td>EGFR-mutant NSCLC – first-line</td></tr>
    <tr><td>Erlotinib (Tarceva®)</td><td>1st generation</td><td>EGFR-mutant NSCLC – first-line; maintenance</td></tr>
    <tr><td>Afatinib (Giotrif®)</td><td>2nd generation</td><td>EGFR exon 19/21 mutant NSCLC – first-line</td></tr>
    <tr><td>Dacomitinib (Vizimpro®)</td><td>2nd generation</td><td>EGFR-mutant NSCLC – first-line</td></tr>
    <tr><td>Osimertinib (Tagrisso®)</td><td>3rd generation</td><td>EGFR T790M+ NSCLC; first-line (exon 19/21)</td></tr>
    <tr><td>Sunvozertinib (Zegfrovy®)</td><td>3rd generation</td><td>EGFR exon 20 insertion NSCLC – FDA approved July 2025</td></tr>
  </tbody>
</table>
<div class="ref-section">
  <p class="ref">[1] Goldman-Cecil Medicine. Elsevier, 2022. EGFR TKI therapy, p. 2025–2027.</p>
  <p class="ref">[9] FDA. Novel Drug Approvals 2025. fda.gov. Accessed June 2026.</p>
</div>

<h3>C. ALK / ROS1 / RET / MET / KRAS Targeted Agents</h3>
<table>
  <thead>
    <tr><th>Drug (Brand Name)</th><th>Target</th><th>Indication</th></tr>
  </thead>
  <tbody>
    <tr><td>Crizotinib (Xalkori®)</td><td>ALK, ROS1, MET</td><td>ALK+ or ROS1+ NSCLC</td></tr>
    <tr><td>Alectinib (Alecensa®)</td><td>ALK</td><td>ALK+ NSCLC – preferred first-line</td></tr>
    <tr><td>Brigatinib (Alunbrig®)</td><td>ALK</td><td>ALK+ NSCLC – first-line</td></tr>
    <tr><td>Lorlatinib (Lorbrena®)</td><td>ALK, ROS1</td><td>ALK+ NSCLC – after 1st/2nd-gen TKI failure</td></tr>
    <tr><td>Ensartinib (Ensacove™)</td><td>ALK</td><td>ALK+ NSCLC first-line – FDA approved Dec 2024</td></tr>
    <tr><td>Entrectinib (Rozlytrek®)</td><td>ROS1, NTRK1-3</td><td>ROS1+ NSCLC; NTRK fusion solid tumours</td></tr>
    <tr><td>Taletrectinib (Ibtrozi™)</td><td>ROS1, NTRK</td><td>ROS1+ NSCLC – FDA approved June 2025</td></tr>
    <tr><td>Selpercatinib (Retevmo®)</td><td>RET</td><td>RET fusion+ NSCLC</td></tr>
    <tr><td>Pralsetinib (Gavreto®)</td><td>RET</td><td>RET fusion+ NSCLC</td></tr>
    <tr><td>Capmatinib (Tabrecta®)</td><td>MET</td><td>MET exon 14 skipping NSCLC</td></tr>
    <tr><td>Tepotinib (Tepmetko®)</td><td>MET</td><td>MET exon 14 skipping NSCLC</td></tr>
    <tr><td>Sotorasib (Lumakras®)</td><td>KRAS G12C</td><td>KRAS G12C+ NSCLC – first approved KRAS inhibitor</td></tr>
    <tr><td>Adagrasib (Krazati®)</td><td>KRAS G12C</td><td>KRAS G12C+ NSCLC – post-platinum chemotherapy</td></tr>
    <tr><td>Dabrafenib + Trametinib</td><td>BRAF V600E + MEK</td><td>BRAF V600E mutant NSCLC</td></tr>
  </tbody>
</table>
<div class="ref-section">
  <p class="ref">[1] Goldman-Cecil Medicine. Elsevier, 2022. Molecular targeted therapy section.</p>
  <p class="ref">[8] Lung Cancer Research Foundation. FDA Approvals in Lung Cancer Treatment.
  lungcancerresearchfoundation.org. Accessed June 2026.</p>
</div>

<h3>D. Immune Checkpoint Inhibitors (ICIs)</h3>
<p>Checkpoint inhibitors targeting the PD-1/PD-L1 axis have transformed treatment of NSCLC without
actionable mutations, particularly in tumours with high PD-L1 expression (≥50%). Also used in
combination with chemotherapy for broader benefit.</p>
<table>
  <thead>
    <tr><th>Drug (Brand Name)</th><th>Target</th><th>Key Indication</th></tr>
  </thead>
  <tbody>
    <tr><td>Pembrolizumab (Keytruda®)</td><td>PD-1</td><td>First-line monotherapy (PD-L1 ≥50%) or + chemotherapy</td></tr>
    <tr><td>Nivolumab (Opdivo®)</td><td>PD-1</td><td>2nd-line NSCLC; neoadjuvant + adjuvant (FDA Oct 2024)</td></tr>
    <tr><td>Atezolizumab (Tecentriq®)</td><td>PD-L1</td><td>First-line NSCLC high PD-L1; extensive-stage SCLC</td></tr>
    <tr><td>Durvalumab (Imfinzi®)</td><td>PD-L1</td><td>Stage III NSCLC post-CRT; limited-stage SCLC (Dec 2024)</td></tr>
    <tr><td>Ipilimumab (Yervoy®)</td><td>CTLA-4</td><td>Combo with nivolumab – PD-L1+ metastatic NSCLC</td></tr>
    <tr><td>Cemiplimab (Libtayo®)</td><td>PD-1</td><td>First-line NSCLC PD-L1 ≥50%</td></tr>
    <tr><td>Tarlatamab (Imdelltra®)</td><td>DLL3 x CD3 bispecific</td><td>Extensive-stage SCLC – full FDA approval Nov 2025</td></tr>
  </tbody>
</table>
<div class="ref-section">
  <p class="ref">[3] Meyer ML et al. Lancet. 2024. PMID: 39121882. Immune checkpoint inhibitors in NSCLC.</p>
  <p class="ref">[8] Lung Cancer Research Foundation. FDA Approvals. lungcancerresearchfoundation.org. 2024–2025.</p>
</div>

<h3>E. Antibody-Drug Conjugates (ADCs) – Emerging Class</h3>
<p>ADCs combine the targeting specificity of monoclonal antibodies with the cytotoxic potency of
chemotherapeutic payloads. They represent one of the most rapidly expanding drug classes in
lung cancer treatment.</p>
<table>
  <thead>
    <tr><th>Drug (Brand Name)</th><th>Target</th><th>Indication and Status</th></tr>
  </thead>
  <tbody>
    <tr><td>Trastuzumab deruxtecan (Enhertu®)</td><td>HER2</td><td>HER2-mutant/overexpressing NSCLC</td></tr>
    <tr><td>Datopotamab deruxtecan (Datroway®)</td><td>TROP-2</td><td>EGFR+ NSCLC post-TKI and chemo – FDA accelerated approval June 2025</td></tr>
    <tr><td>Telisotuzumab vedotin (Emrelis™)</td><td>c-MET</td><td>Non-squamous NSCLC with high MET overexpression – FDA approved May 2025</td></tr>
    <tr><td>Zenocutuzumab (Bizengri®)</td><td>NRG1 fusion</td><td>NRG1 fusion+ NSCLC – FDA accelerated approval Dec 2024</td></tr>
  </tbody>
</table>
<div class="ref-section">
  <p class="ref">[8] Lung Cancer Research Foundation. FDA Approvals in Lung Cancer Treatment. 2024–2025.
  lungcancerresearchfoundation.org. Accessed June 2026.</p>
  <p class="ref">[9] FDA. Novel Drug Approvals 2025. fda.gov. Accessed June 2026.</p>
</div>

<h3>F. Anti-Angiogenic Agents</h3>
<table>
  <thead>
    <tr><th>Drug (Brand Name)</th><th>Target / Class</th><th>Indication</th></tr>
  </thead>
  <tbody>
    <tr><td>Bevacizumab (Avastin®)</td><td>VEGF-A monoclonal antibody</td><td>Non-squamous NSCLC – in combination with chemotherapy</td></tr>
    <tr><td>Ramucirumab (Cyramza®)</td><td>VEGFR-2 monoclonal antibody</td><td>NSCLC second-line + docetaxel; also + erlotinib (EGFR mutant)</td></tr>
    <tr><td>Nintedanib (Vargatef®)</td><td>VEGFR, PDGFR, FGFR TKI</td><td>Adenocarcinoma NSCLC second-line + docetaxel (EMA approved)</td></tr>
  </tbody>
</table>
<div class="ref-section">
  <p class="ref">[1] Goldman-Cecil Medicine. Elsevier, 2022. Anti-angiogenic therapy in lung cancer.</p>
</div>

<div class="note">
  <strong>2025 FDA Approvals Highlight:</strong> Seven new approvals were granted for NSCLC alone in 2025
  – sunvozertinib (EGFR exon 20), taletrectinib (ROS1+), telisotuzumab vedotin (MET-high),
  datopotamab deruxtecan (EGFR+ post-TKI), sevabertinib (HER2 TKD-mutant), tarlatamab full approval
  (SCLC), and lurbinectedin + atezolizumab (SCLC maintenance) – reflecting the unprecedented pace of
  targeted therapy development.
  <br><br>
  <em>References: [9] FDA Novel Drug Approvals 2025; [10] ASCO Post Dec 2025; [11] PMC12873738.</em>
</div>

<!-- ══════════ REFERENCES ══════════ -->
<div class="page-break"></div>
<div class="q-heading">References</div>

<div class="ref-list">
  <ol>
    <li>Goldman-Cecil Medicine, International Edition, 2-Volume Set. Elsevier, 2022. Chapter 177:
    Bronchogenic Lung Cancer (Definition, Epidemiology, Risk Factors, Molecular Pathogenesis,
    Oncogenes, Tumor Suppressor Genes, Staging, Treatment), pp. 2024–2031.</li>
    <li>Smolarz B, Łukasiewicz H, Samulak D, Piekarska E, Kołaciński R, Romanowicz H. Lung
    Cancer–Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature).
    International Journal of Molecular Sciences. 2025;26(5):2049. doi:10.3390/ijms26052049.
    PMID: 40076671.</li>
    <li>Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Jänne PA, Peters S. New promises and
    challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024 Aug 24.
    doi:10.1016/S0140-6736(24)01029-8. PMID: 39121882.</li>
    <li>Tata Memorial Centre. Official Website. Available at: https://tmc.gov.in. Accessed June 2026.</li>
    <li>Wikipedia: Tata Memorial Centre. https://en.wikipedia.org/wiki/Tata_Memorial_Centre.
    Accessed June 2026.</li>
    <li>Pramesh CS, et al. (Corresponding: Dept of Medical Oncology, Tata Memorial Hospital). Uniqueness
    of lung cancer in Southeast Asia. PMCID: PMC11328770. PMID: 39157507. Published 2024.</li>
    <li>Press Information Bureau, Government of India. Parliament Question: Cancer Treatment Centres
    and Hospitals Under Tata Memorial Centre and DAE. pib.gov.in. Accessed June 2026.</li>
    <li>Lung Cancer Research Foundation. FDA Approvals in Lung Cancer Treatment.
    https://www.lungcancerresearchfoundation.org/research/why-research/treatment-advances.
    Accessed June 2026.</li>
    <li>U.S. Food and Drug Administration. Novel Drug Approvals for 2025.
    https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025. Accessed June 2026.</li>
    <li>ASCO Post. New FDA-Approved Oncology Drugs and Label Updates Between December 1, 2024 and
    November 19, 2025. ascopost.com. Accessed June 2026.</li>
    <li>PMC. A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets.
    PMC12873738. Accessed June 2026.</li>
    <li>Murray &amp; Nadel's Textbook of Respiratory Medicine, 2-Volume Set. Elsevier, 2022. Chapters:
    Treatment of Non-Small Cell Lung Cancer by Stage; Staging of Lung Cancer.</li>
    <li>Bouchard N, Daaboul N. Lung Cancer: Targeted Therapy in 2025. Curr Oncol. 2025 Mar 2.
    PMID: 40136350.</li>
    <li>Jeon H, Wang S, Song J. Update 2025: Management of Non-Small-Cell Lung Cancer. Lung.
    2025 Mar 25. PMID: 40133478.</li>
  </ol>
</div>

<div class="footer">
  Document prepared for: MPharm Research Project Interview – Tata Memorial Centre, Mumbai | June 2026
</div>

</body>
</html>